Pharmacoepidemiology evaluation of bumetanide as a potential candidate for drug repurposing for Alzheimer's disease
Morales J, Gabriel N, Natarajan L, LaCroix A, Shadyab A, Xu R, Silverman J, Feldman H, Hernandez I, Collaboration F. Pharmacoepidemiology evaluation of bumetanide as a potential candidate for drug repurposing for Alzheimer's disease. Alzheimer's & Dementia 2024 PMID: 39030734, DOI: 10.1002/alz.13872.Peer-Reviewed Original ResearchRisk of ADCross-sectional analysis of electronic health recordsAnalysis of electronic health recordsAD riskAssociated with risk of ADAssociated with AD riskAssociated with decreased prevalenceElectronic health recordsRetrospective cohort study designMedicare claims dataCohort study designCox proportional hazards regressionAssociated with riskCross-sectional analysisProportional hazards regressionPrevalence of ADMultiple sensitivity analysesAlzheimer's diseaseHealth recordsMedicare beneficiariesMedicare dataClaims dataStudy designHazards regressionPatient characteristics